as well as a €1 million loan from Bpifrance
PARIS, July 19, 2021 /PRNewswire/
PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announced today that it raised an additional €2.6 million ($3 million) in an extension of its Series A financing round, bringing the total raised in this round to €5.4 million ($6.4 million). This new funding comprises €1.6 million in equity from Anaxago, i&i Prague and BADGE as well as a €1 million loan from Bpifrance.
This increased financial support highlights the potential of PEP-010, as well as PEP-Therapy s Cell Penetrating & Interfering Peptide (CP&IP) technology platform, which was first developed at Sorbonne University and Institut Curie.
PEP-Therapy extends Series-A financing, raising a total of €5 4 million to progress the clinical development of its lead candidate PEP-010
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Cubbit Raises €7M in Funding
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.
Italo | il Pd | C è chi ha lavorato per ridurre il gap infrastrutturale e chi oggi fa lo striscione
zazoom.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zazoom.it Daily Mail and Mail on Sunday newspapers.
April 29, 2021
April 29, 2021 | Illumina joins the Gates Foundation in a global pathogen genomics initiative, new money for immune profiling, and Benchling nets $200M for their cloud platform.
$375M: Fund for Growth-Stage Medtech, Digital Health
Endeavour Vision has closed Endeavour Medtech Growth II (EMG II) LP at USD 375 million in capital commitments. The fund will pursue the same strategy as its predecessor: to support growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems. Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices, and high-net-worth individuals. EMG II LP builds on Endeavour Vision’s two decades of healthcare investing, which to date has included over USD 500 million invested in 42 companies 21 of which have exited via an acquisition or IPO. The fund has already supported seven companies with investm